Summary
Highlights
Initially, neuromyelitis optica (NMO) was thought to be a variant of multiple sclerosis (MS), but it's now recognized as a separate disease. NMO is an immune-mediated condition affecting the optic nerves and spinal cord.
NMO commonly presents with symptoms such as vision loss and spinal issues. It predominantly affects women and has a higher prevalence in certain ethnicities. It is a rare disease affecting fewer than 1 in 20,000 people.
Diagnosis of NMO often involves identifying anti-aquaporin 4 antibodies. Distinct criteria exist based on whether these antibodies are present. The presence of certain brain and spinal lesions helps differentiate NMO from MS.
Without treatment, NMO can result in frequent attacks leading to disability. However, progression is mostly relapsing, unlike the often gradual progression seen in MS.
Treatment involves acute management with steroids or plasmapheresis and long-term prevention with drugs like rituximab, which depletes B cells. New FDA-approved drugs such as Solarus, Uplizna, and Enspring have shown effectiveness in clinical trials.
Differences between NMO and MS include lesion patterns, antibody presence, and cerebrospinal fluid findings. Misdiagnosis with MS is common due to the rarity of NMO.
Clinical trials indicate the efficacy of new treatments. The success of these studies underscores the importance of ongoing research in improving outcomes for NMO patients.